ProMIS Neurosciences Inc PMN

Yes -- Dare we say --- From Alzforum

[retiredcop]

https://www.alzforum.org/news/conference-coverage/dare-we-say-consensus-achieved-lecanemab-slows-disease

[retiredcop]

This is great ! Some thing that PMN can now compare with during clinical...  1) Four speakers reported that secondary and biomarker measures were consistent, and of similar magnitude to the effect on primary. 2) Overall, lecanemab appeared to slow disease progression by about one-quarter, 3) and caused the brain edema known as ARIA-E in one of eight participants.

[Gbathat]

Biomarker data in Phase I might allow PMN to 'catch up' to Acumen.... I don't think Acumen built biomarker data collection into their PhI but they'll include it in Ph2/3 milestones https://www.jpreventionalzheimer.com/6565-acu193-a-monoclonal-antibody-that-selectively-binds-soluble-asX-oligomers-development-rationale-phase-1-trial-design-and-clinical-development-plan.html 

[M101]

Re Acumen, whenever I read their stuff I'm struck by the lack of any mention of misfolding. Of course the same could be said for other PMN competitors but it's more striking with Acumen because their stage of development is so close to that of Promis.  So when I read their stuff I'm looking for the sort of careful wording that disinvites any discussion of why certain oligomers are

[M101]

absolutely! if you set the bar low enough you can jump over it by a really impressive %. now let's see them market this baby like a Zelensky pill!